SB 11285
- Generic Name
- SB 11285
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- invoX Pharma Limited
- Target Recruit Count
- 61
- Registration Number
- NCT04096638
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath